Supplementary Figure 3 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

作者：Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, Guilherme Harada, Jessica Lee, Joao V. Alessi, Adriana Barrichello, Victor R. Vaz, Giuseppe Lamberti, Alessandro Di Federico, Malini Gandhi, Dimitris Gazgalis, William W. Feng, Jie Jiang, Simon Baldacci, Marie-Anaïs Locquet, Felix H. Gottlieb, Monica F. Chen, Elinton Lee, Danielle Haradon, Anna Smokovich, Emma Voligny, Tom Nguyen, Vikas K. Goel, Zachary Zimmerman, Sumandeep Atwal, Xinan Wang, Magda Bahcall, Rebecca S. Heist, Sumaiya Iqbal, Nishant Gandhi, Andrew Elliott, Ari M. Vanderwalde, C. Patrick, Balázs Halmos, Stephen V. Liu, Jianwei Che, Alexa B. Schrock, Alexander Drilon, Pasi A. Jänne, Mark M. Awad · 年份：2026 · DOI：10.1158/2159-8290.32698173 · 研究领域：Lung Cancer Treatments and Mutations、Liver physiology and pathology、Melanoma and MAPK Pathways

<p>Comparison of missense MET TKD defined as “probably pathogenic” and “probably benign” according to three in silico tools. Comparison of (A) secondary structure features, (B) relative solvent accessible surface area (RSA), and (C) mutant amino acid properties of missense MET TKD mutations of unknown biological function according to OncoKB. Mutations were defined as “probably pathogenic” for likely pathogenicity across all three tools and as “probably benign” for likely benign across all three scores. OR: odds ratio; 95% CI: 95% confidence interval.</p>